News AstraZeneca and Lilly’s Alzheimer’s drug fails trial The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results.
News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.
News vTv's azeliragon is latest Alzheimer's drug failure vTv to stop all studies after STEADFAST trial failure
News Celgene pursues neuro breakthrough with $150m Prosena deal Celgene is pushing further into the field of neuroscience and dementia research with an alliance with Dublin-based biotech Prosena.
Views & Analysis Digital in action against Alzheimer’s disease Digital technologies are both helping to transform the public’s perception of dementia, and enabling everyone to help scientific research into the disease by playing a smartphone game that tests navigation skills.
News Concerns mount over Biogen Alzheimer's drug FDA announces guidance to encourage development of new drugs
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
